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Abstract
Background—Patients with familial ad­
enomatous polyposis are not only at high 
risk of developing adenomas in the 
colorectum but a substantial number of 
patients also develop polyps in the duo­
denum. Because tream ent of duodenal 
polyps is extremely difficult and it is 
unknown how many patients ultimately 
develop duodenal cancer, the value of 
surveillance of the upper digestive tract is 
uncertain.
Aim s— (1) To assess the cumulative risk of 
duodenal cancer in a large series of poly­
posis patients, (2) To develop a decision 
m odel to establish whether surveillance 
would lead to increased life expectancy. 
Methods—Risk analysis was performed 
in 155 Dutch polyposis families including 
601 polyposis patients, and 142 Danish 
fam ilies including 376 patients. Obser­
vation time was from birth until date o f 
last contact, death, diagnosis of duodenal 
cancer, or closing date of the study. 
Results—Seven Dutch and five Danish 
patients developed duodenal cancer. The 
lifetim e risk of developing this cancer by 
the age o f 70 was 4% (95% confidence 
interval 1-7%) in the Dutch series and 3% 
(95% confidence interval 0-6%) in the 
Danish series. D ecision analysis showed 
that surveillance led to an increase in life 
expectancy by seven months.
Conclusions—Surveillance of the upper 
digestive tract led to a moderate gain in 
life expectancy. Future studies should 
evaluate whether this increase in life 
expectancy outweighs the morbidity of 
endoscopic examination and proximal 
pancreaticoduodenectomy.
(Gut 1997; 40: 716-719)
Keywords: familial adenomatous polyposis, duodenal 
cancer, surveillance, decision analysis, 
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Familial adenomatous polyposis (FAP) or 
Bussey-Gardner polyposis is an autosomal 
dominant disease due to a mutated aden­
omatous polyposis coli (APC) gene and is 
characterised by the development of hundreds 
of adenomas in the colon.1' 3 Since the disease 
was first recognised, there have been numerous 
reports of other lesions outside the colon. 
The spectrum of lesions reported in FAP 
includes multiple osteomas of the cranium and 
mandibles, multiple epidermoid cysts of the 
skin, dental abnormalities, desmoid tumours of
the abdominal wall and abdomen, bilateral 
patches of congenital hypertrophy of the 
retina pigment epithelium, and ftindic gland 
polyposis.4 5
During the 1970s, an increasing number of 
case reports of FAP patients with malignancy 
of the periampullary region and proximal duo­
denum appeared,6 7 These reports focused 
attention on the upper gastrointestinal (GI) 
tract and led to series of reports on gastroduo- 
denoscopy of groups of polyposis patients. 
Most recorded that at least two thirds of the 
polyposis patients also had duodenal aden­
omas.8“15 The first question to arise at that time 
was: do the adenomas of the duodenum follow 
the adenoma-carcinoma sequence observed in 
the colorectum? At present, there is ample 
evidence suggesting that this is the case. 
Duodenal or periampullary adenocarcinoma 
has been found to occur in patients with FAP 
at a much higher frequency compared with the 
general population16 17 and 40% of patients 
with duodenal cancer have synchronous duo­
denal adenomas.18
Despite this information it is still unknown 
how many patients with duodenal polyps 
ultimately develop duodenal cancer. As such 
information should be available before the 
introduction of a large scale surveillance pro­
gramme for patients with polyposis, we evalu­
ated the lifetime risk of duodenal cancer in a 
large series of patients with polyposis from the 
Polyposis Registries in The Netherlands and 
Denmark. In addition, a decision analysis 
model was developed for prediction of whether 
surveillance of the upper GI tract would lead 
to an increased life expectancy.
Methods
T H E  D U T C H  AND D A N ISH  POLYPOSIS REGISTRIES
Families suspected of FAP are referred to the 
registries from all parts of both countries.19 
Personal data, results of investigation, patho­
logy reports, and results of treatment are 
collected for the registries. The criteria used for 
the diagnosis of an FAP family were that there 
should be at least one relative with more than
100 colorectal adenomas, or that linkage or
)
mutation analysis had proven that the APC 
gene was responsible for the disease in the 
family.
RISK ANALYSIS
For risk assessment, patients with polyposis 
were studied with respect to risk of the
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Decision tree for a 30 year old man with familial adenomatous polyposis.
development of duodenal cancer from birth 
until death. The data were analysed by life 
table analysis methods. Observation time was 
until date of last contact, death* date of 
diagnosis of a duodenal cancer* or closing date 
of the study* 31 December 1995.
D E C ISIO N  ANALYSIS
We applied the technique of decision analysis 
to a hypothetical male polyposis patient* 30 
years of age* who had undergone colectomy 
and ileorectal anastomosis. The first step was 
to identify all the alternative actions* treat­
ments* and outcomes that could occur for the 
patient in question. On the basis of this* a 
decision model (shown in the Figure) that 
displays these elements in their proper time 
sequence was developed. Points where the tree 
branches (“nodes59) are square (“choice 
nodes55) when they imply a decision under the 
control of the physician* and round (“chance 
nodes55) if a chance outcome occurs.
Results
RISK ANALYSIS
On 31 December 1995* the Dutch Popyposis 
Register included about 200 families with FAP. 
Data collection was completed in the first 155 
families and these families were selected for the 
present study. The 155 families included 711 
patients with FAP. The diagnosis of FAP was 
confirmed by pathology and/or medical reports 
in 601 patients. One hundred and eighteen 
patients died; the cause of death is known in 
91% of the patients. Among the 601 patients* 
seven developed duodenal cancer (including 
one suspected case). The mean age at diag­
nosis of duodenal cancer was 47 years (range 
39-53). The cumulative risk of developing 
duodenal cancer by age 70 was 4% (95%
confidence interval 1-7%). The number of 
patients at risk by age 70 was 27.
On 31 December 1995* the Danish Poly­
posis Register included 142 FAP families with 
a completed data collection* including 454 
patients of whom 376 had a histologically 
verified FAP. The cause of death is known 
for all 160 deceased patients. In five patients 
data were insufficient. Of the remaining 371 
affected patients* five developed duodenal 
cancer; die mean age at diagnosis was 51 years 
(range 43—77). The cumulative risk of devel­
oping duodenal cancer by age 70 was 3% (95% 
confidence interval 0-6%). The number of 
patients at risk by age 70 was nine.
D E C ISIO N  ANALYSIS
The decision tree for the 30 year old polyposis 
patient with corresponding probabilities is 
shown in the Figure. We assumed that the life 
expectancy of a 30 year old polyposis patient 
would be shortened due to desmoid disease* 
the mortality due to secondary rectal surgery* 
and the mortality due to rectal cancer. There­
fore* we estimated that the average life expec­
tancy of this 30 year old patient would be 40 
years instead of 45 years. For staging of 
duodenal polyposis in most studies use was 
made of the so-called Spigelman classifi­
cation. 14 This staging system is based on a set 
of arbritary scores using postulated adenoma/ 
cancer risk factors. These are the architecture 
(“villousness13)* the degree of dysplasia* and 
the size and number of the duodenal polyps, 
Stage I represents minor disease and stage IV 
indicates major or advanced duodenal poly­
posis (Table I). When stage IV duodenal 
polyposis is found* surgical intervention may 
be considered. The probability of finding 
Spigelman stage IV is based on findings of two 
prospective studies on the natural history of 
duodenal adenomatosis.
718 Vasen, Billow, Myrhojj A4aihus- Vliegen3 Griffioen, Buskens} et al
t a b l e  i Classification of duodenal adenomas according to 
SpigelmanH
Polyps
Points
1 2 3
N um ber <4 5-20 >20
Size (mm) 0-4 5-10 >10
Histology Tubular Tubulo-villous Villous
Dysplasia M ild M oderate Severe
Spigelman stage I: 1-4; stage II: 5-6; stage III: 7-8; stage IV: 
9-12 points.
One analysis was conducted at the St Mark’s 
Polyposis Registry in London14 and the other 
in five European countries.15 The British study 
showed that 11(11%) out of 102 FAP patients 
had stage IV duodenal polyposis. In the 
European multicentre study* 27 patients out of 
310 (9%) had stage IV duodenal polyposis. 
In the multi centre study* 7% of the patients 
aged between 20 and 40 years* and 11% of 
those aged between 40 and 60 years had 
stage IV duodenal adenomatosis (personal 
communication* S Biilow). The cumulative 
risk of developing stage IV adenomatosis is 
therefore at least 11%. The mean age of the 
patients identified with Spigelman stage IV was 
51 years in the British study and 38 years in 
the multi centre study. On these grounds we 
estimated that the average age of patients who 
reached stage IV duodenal polyposis would be 
45 years. If a pancreaticoduodenotomy is 
performed and the patient dies as a result 
of complications of this procedure* the aver­
age life expectancy of a 30 year old patient 
would amount to 15 years. The periopera­
tive mortality of pancreaticoduodenectomy has 
declined during the past decade and is now 
about 5%.
The cumulative risk of duodenal cancer by 
age 70 in the present series is 3-4%. The mean 
age at diagnosis of duodenal cancer in this 
study and in three others was about 50 years. 
The life expectancy of a patient who develops 
duodenal cancer is estimated at two years. 
Hence* the life expectancy of the hypothetical 
30 year old patient is on average 22 years if he 
develops duodenal cancer.
We then worked our way back through the 
decision tree by “folding it back” from right to 
left. By multiplying the life expectancy by the 
probabilities of occurrence of each option* and 
summing them for each branch* we could
t a b l e  n  The impact of various probabilities of developing 
duodenal canccr3 stage IVduodenal adenomatosis> and 
perioperative mortality on life expectancy
Life expectancy (y)
Surveillance No suweillcince
Probability of duodenal cancer (%)
4 39*9 39*3
10 39*9 38*2
15 39-9 37*3
Probability of stage I V  duodenal adenomatosis (%)
\ 1 39-9 39*3
15 39*8 39-3
20 39*7 39’3
Probability of perioperative mortality (%)
2 39*9 39*3
4 39*9 39*3
6 39*8 39-3
assign life expectancies to the various nodes. 
The calculations showed that the option of 
surveillance led to an increase in life expec­
tancy by seven months. The key variables -  
the cumulative risk of stage IV duodenal 
adenomatosis* duodenal cancer* and the risk of 
mortality due to pancreaticoduodenotomy -  
were varied over a plausible range to assess 
their impact on the outcome of the model 
(Table II). The probability of developing 
duodenal cancer appeared to be the most 
important variable.
Discussion
After the realisation that a majority of patients 
with polyposis develop adenomas in the duo­
denum* many investigators recommended 
surveillance of the upper GI tract. However* 
before establishing such a surveillance pro­
gramme* a more critical evaluation of the pros 
and cons of surveillance should be performed. 
In particular* the difficulties for effective 
treatment posed by duodenal adenomas make 
the benefit of surveillance of the upper GI tract 
questionable.
In the assessment of population screening* 
the criteria formulated by Wilson and Jungner20 
are usually applied. These criteria are also 
appropriate in the assessment of surveillance 
of high risk groups such as patients with 
polyposis. According to these criteria* the natu­
ral history of duodenal adenomas should be 
known* a curative treatment should be avail­
able* and there should be evidence that early 
treatment leads to an improved prognosis.
With respect to the natural history of 
duodenal adenomas* the most urgent question 
is “do the duodenal polyps have the same 
malignant potential as the colonic polyps?” 
Earlier studies17 indicated that the relative risk 
of duodenal cancer in FAP was very high* but 
such information is less useful in the decision 
making process* because the incidence of 
duodenal cancer in the general population is 
extremely low. Much more important would 
be to know the lifetime risk of developing 
duodenal cancer. The present study revealed 
that the cumulative risk of duodenal cancer 
was less than 5% by the age of 70. Although 
prospective studies are needed to confirm our 
findings* such studies have the disadvantage 
that the screening examinations will inevitably 
lead to early detection of premalignant disease 
and to early surgical intervention* which will 
interfere with the assessment of the duodenal 
cancer risk.
The treatment of duodenal adenomas in our 
patients is limited by a number of factors. 
Endoscopic snaring may be made impossible 
by the presence of large numbers of polyps or 
by the usual sessile nature of the polyps. 
Endoscopic electrocoagulation* if repeated 
very often* will lead to considerable scarring* 
which in the periampullary area might cause 
strictures. Laser ablation of polyps via the 
endoscope can be used* but carries the risk of 
duodenal perforation. Polyp removal by (sur­
gical) duodenotomy consisting of submucosal 
infiltration and local excision of all polyps is
Short segment Barrett’s oesophagus 719
not recommended, because a recent study has 
shown recurrence in all patients treated by this 
technique within a short time.21 To summarise, 
the only curative treatment appears to be a 
proximal pancreaticoduodenotomy, Such an 
operation has considerable potential morbidity 
and mortality which makes the indication for 
and the timing of surgery extremely difficult. 
Criteria of size, rapid growth, polyp induration, 
or consistently severe dysplasia or villous 
change suggest that intervention is necessary. 
In the above mentioned British study, among 
the 10 patients with stage IV adenomatosis at 
the first endoscopy, one developed duodenal 
cancer and two other patients are suspected of 
having this type of cancer.22 Thus surgery may 
be considered in patients that consistently have 
stage IV duodenal adenomatosis.
Evidence that early treatment leads to 
improvement of the prognosis is not yet 
available, and it will probably take a long time 
to collect such information. The best way to 
demonstrate the benefits of surveillance would 
be by randomised controlled studies showing 
a higher survival rate. Such studies will, how­
ever, be difficult to carry out in view of the 
extremely high risk of prenialignant duodenal 
disease. Therefore, we decided to apply de­
cision analysis to predict whether surveillance 
might lead to an increase in life expectancy. 
The calculations showed that surveillance 
increased the life expectancy by seven months 
if surgery was performed after detection of 
stage IV adenomatosis. Sensitivity analysis 
showed that the probability of duodenal cancer 
had the strongest effect on the outcome com­
pared with the probability of developing duo­
denal adenomatosis stage IV or perioperative 
mortality.
To summarise, the present analysis revealed 
that surveillance may lead to a moderate gain 
in life expectancy. Therefore, before startin 
surveillance of the upper digestive tract, it is 
important to explain to the patients that the 
risk of developing duodenal cancer is relatively 
low and that the only curative treatment for 
severe duodenal adenomatosis is a major 
operation with substantial morbidity and 
mortality (in addition to the morbidity from 
duodenoscopy). On the basis of this infor­
mation the patients may be able to decide 
whether the potential gain in life expectancy 
outweighs the adverse effects of surveillance 
and treatment. If the patient prefers to be 
under surveillance, the screening protocol 
should start by the age of 30 years. Starting at 
an earlier age can be considered to offer no 
clinical benefit, as reports of duodenal cancer 
before this age are extremely rare. The recom­
mended interval between examinations is one 
to three years depending on the findings. 
Ideally, the results should be collected in a 
uniform manner at a regional or national 
registry which will permit future evaluation.
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